Bloomberg: DNA Fingerprinting Throws Doubt on Glaxo Malaria Vaccine Effort
“Groundbreaking research has shown the potentially deadly malaria parasite has greater genetic diversity than scientists previously understood, a finding that throws doubt on the efficacy of vaccines in development by companies such GlaxoSmithKline Plc. … The research, published Tuesday in the Proceedings of the National Academy of Sciences, is the first to rely on DNA fingerprinting to show how malaria’s genetic diversity enables it to evade the human immune system and establish a chronic infection…” (Gale, 5/3).